Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Guanidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 2/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetamidine SCHEMBL6287555 | 0.91 | BLM (0.43) | KDM4EBLMCYP2D6CYP2C19NPSR1 | |
| Thiourea SCHEMBL7362564 | 0.88 | KDM4E (0.42) | KDM4EBLMCYP2D6CYP2C19NPSR1 | |
| SCHEMBL6737394 | 0.88 | KDM4E (0.42) | KDM4EBLMCYP2D6CYP2C19NPSR1 | |
| SCHEMBL6286669 | 0.84 | KDM4E (0.39) | KDM4EBLMCYP2D6CYP2C19NPSR1 | |
| SCHEMBL6289391 | 0.84 | KDM4E (0.39) | KDM4EBLMCYP2D6CYP2C19NPSR1 | |
| Hydrazine SCHEMBL679587 | 0.83 | — | — | |
| Methylamine SCHEMBL143865 | 0.83 | — | — | |
| Hydroxyamine SCHEMBL27900806 | 0.83 | — | — | |
| SCHEMBL27308161 | 0.83 | TSHR (0.50) | KDM4ECA2CA1TSHRUSP2 | |
| SCHEMBL5991 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118240806-A | Liquid thrombin reagent | 仪器实验室公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-114072378-B | Process (III) for preparing metastable crystal modifications of N- (aminoiminomethyl) -2-glycine | 澳泽化学特罗斯特贝格有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-109566664-A | A kind of aquatic products, livestock and poultry disinfectant and its preparation and application | 南京瑞碧斯生物科技有限公司 | 2019-04-05 | — | — | CN | disclosed |
| US-20100222580-A1 | Process For The Preparation Of Onium Alkylsulfates Having A Low Halide Content | MERCK PATENT GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| EP-1828142-B1 | METHOD FOR PRODUCING ONIUM ALKYL SULFATES WITH A LOW HALOGENIDE CONTENT | MERCK PATENT GMBH (DE) | 2010-06-02 | — | — | EP | disclosed |
| EP-1828142-A1 | METHOD FOR PRODUCING ONIUM ALKYL SULFATES WITH A LOW HALOGENIDE CONTENT | Merck Patent GmbH (DE) | 2007-09-05 | — | — | EP | disclosed |
| CN-1301978-C | Preparation of 2-methyl-4-pyrimidone | LUYUAN PHARMACEUTICAL CO LTD D (CN) | 2007-02-28 | — | — | CN | disclosed |
| WO-2006063654-A1 | METHOD FOR PRODUCING ONIUM ALKYL SULFATES WITH A LOW HALOGENIDE CONTENT | MERCK PATENT GMBH (DE) | 2006-06-22 | — | — | WO | disclosed |
| CN-1491939-A | Hexa alkyl guanidine salt ion liquid and preparing process | 中国科学院长春应用化学研究所 | 2004-04-28 | — | — | CN | disclosed |
| US-5635322-A | Process for developing and overcoating migration imaging members | XEROX CORPORTION (US) | 1997-06-03 | — | — | US | disclosed |
| US-5534374-A | Migration imaging members | XEROX CORPORATION (US) | 1996-07-09 | — | — | US | disclosed |
| EP-0673781-A1 | Recording sheets containing amine salts and quaternary choline halides | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | disclosed |
| US-4565826-A | HYPOTENSIVE, CARDIONASCULAR, ANTIULCER, ANTISECRETORY, GASTROINTESTINAL DISORDERS | WILLIAM H. RORER, INC. (US) | 1986-01-21 | — | — | US | disclosed |
| US-4564640-A | Amidinoureas substituted in both the urea and amidino nitrogen positions | WILLIAM H. RORER, INC. (US) | 1986-01-14 | — | — | US | disclosed |
| EP-0078839-A4 | HETEROCYCLIC AMIDINOUREAS. | RORER INTERNAT OVERSEAS INC (US) | 1984-07-25 | — | — | EP | disclosed |
| US-4436911-A | HYPOTENSIVE, ANTISPASMODIC, ANTIULCER, ANTIPARASITIC | WILLIAM H. RORER, INC. (US) | 1984-03-13 | — | — | US | disclosed |
| EP-0078839-A1 | HETEROCYCLIC AMIDINOUREAS | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1983-05-18 | — | — | EP | disclosed |
| WO-1982004047-A1 | HETEROCYCLIC AMIDINOUREAS | RORER INT OVERSEAS (US) | 1982-11-25 | — | — | WO | disclosed |
| US-4178387-A | ADMINISTERING AMIDINOUREAS | WILLIAM H. RORER, INC. (US) | 1979-12-11 | — | — | US | disclosed |
| US-4147804-A | ANTIARRHYTHMIA AGENTS | WILLIAM H. RORER, INC. (US) | 1979-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222580-A1 | Process For The Preparation Of Onium Alkylsulfates Having A Low Halide Content | STS, MRPS35, ARSA | KDM4E 733/4885BLM 4589/4885CYP2D6 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.